



University of
Massachusetts
Amherst

Embryonic Exposures to Perfluorooctanesulfonic Acid (PFOS) Disrupt Pancreatic Organogenesis in the Zebrafish, *Danio rerio*

Item Type	article;article
Authors	Sant, Karilyn E.;Jacobs, Haydee M.;Borofski, Katrina A.;Moss, Jennifer B.;Timme-Laragy, Alicia R.
Download date	2024-10-06 10:31:58
Link to Item	https://hdl.handle.net/20.500.14394/22924

15 **ABSTRACT**

16 Perfluorooctanesulfonic acid (PFOS) is a ubiquitous environmental contaminant, previously
17 utilized as a non-stick application for consumer products and firefighting foam. It can cross the
18 placenta, and has been repeatedly associated with increased risk for diabetes in epidemiological
19 studies. Here, we sought to establish the hazard posed by embryonic PFOS exposures on the
20 developing pancreas in a model vertebrate embryo, and develop criteria for an adverse outcome
21 pathway (AOP) framework to study the developmental origins of metabolic dysfunction.
22 Zebrafish (*Danio rerio*) embryos were exposed to 16, 32, or 64 μ M PFOS beginning at the mid-
23 blastula transition. We assessed embryo health, size, and islet morphology in *Tg(insulin-GFP)*
24 embryos at 48, 96 and 168 hpf, and pancreas length in *Tg(ptf1a-GFP)* embryos at 96 and 168
25 hpf. QPCR was used to measure gene expression of endocrine and exocrine hormones, digestive
26 peptides, and transcription factors to determine whether these could be used as a predictive
27 measure in an AOP. Embryos exposed to PFOS showed anomalous islet morphology and
28 decreased islet size and pancreas length in a U-shaped dose-response curve, which resemble
29 congenital defects associated with increased risk for diabetes in humans. Expression of genes
30 encoding islet hormones and exocrine digestive peptides followed a similar pattern, as did total
31 larval growth. Our results demonstrate that embryonic PFOS exposures can disrupt pancreatic
32 organogenesis in ways that mimic human congenital defects known to predispose individuals to
33 diabetes; however, future study of the association between these defects and metabolic
34 dysfunction are needed to establish an improved AOP framework.

35

36 Keywords: pancreas development, insulin, islets, β cells, embryo, exocrine pancreas

37

38 Capsule: Aberrant pancreas development is a novel hazard of embryonic PFOS exposures

39

40 **Highlights:**

- 41 • Developmental PFOS exposures decreased the size of beta cell mass in the primary Islet of
42 Langerhans in the zebrafish embryo.
- 43 • PFOS exposures increased the incidence of islet malformations and shortened pancreas length,
44 which recapitulate congenital defects known to increase risk for diabetes in humans.
- 45 • Abnormal pancreas development is a previously unidentified hazard of developmental PFOS
46 exposures.

47

48

49

50

51 INTRODUCTION

52 The global prevalence of diabetes has been rapidly increasing in recent decades (National
53 Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2014). Both Type 1 and Type
54 2 diabetes manifest as hyperglycemia related to reduced beta cell mass, either due to
55 autoimmune destruction of the insulin-producing beta cells in Type 1, or insulin resistance with
56 loss of beta cell mass in Type 2 diabetes. Recent studies have demonstrated that chemical
57 exposures are capable of reducing beta cell mass. However, the consequences of developmental
58 exposures on the rapidly growing and maturing islets require identification.

59 While genetic sources of metabolic dysregulation are known to contribute to diabetic
60 etiology in the adult, there is a growing body of evidence supporting the link between
61 developmental environmental exposures and occurrence of diabetes later in life (Inadera, 2013;
62 Simmons, 2006; Simmons, 2007). Numerous studies have investigated how physiological and
63 pharmacological conditions influence beta cell health in adolescents and adults; however, very
64 little is known about how these conditions may impact the sensitive developing pancreas, and
65 whether these developmental consequences may manifest as metabolic dysfunction in adulthood.
66 These gaps in our knowledge warrant investigation to produce a robust, predictive adverse
67 outcome pathway (AOP) to study the developmental origins of diabetes and metabolic disease.

68 Islet architecture plays an important role in the governance of islet physiology and
69 endocrinology, and variant morphologies can be observed concurrent with diabetic phenotypes
70 and hyperglycemia (Bosco et al., 2010; Cabrera et al., 2006; Kilimnik et al., 2011; Kim et al.,
71 2009). An increased risk of metabolic disease and pancreatitis has been associated with four
72 congenital pancreatic malformations found in the human population: pancreas divisum, ectopic
73 pancreatic tissue, dorsal pancreatic agenesis, and annular pancreas. Pancreas divisum and ectopic

74 pancreatic tissue are predicted to occur in approximately 10% of the population (Prasad et al.,
75 2001; Varshney and Johnson, 1999; Vaughn et al., 1998), while the other two anomalies are
76 considered rare. Unlike most congenital defects which manifest as life-threatening or debilitating
77 conditions, these pancreatic defects result in largely mild phenotypic outcomes and thus often go
78 undetected, although they have been associated with increased risk for diabetes and pancreatitis
79 in adulthood (Balakrishnan et al., 2006; Concepcion et al., 2014; Gentile and Fiorente, 1999;
80 Gilinsky et al., 1987; Lindstrom et al., 1990; Mitchell et al., 2004; Shoji et al., 2013). The causes
81 of these malformations are largely unknown, but do not appear to be genetic in nature. This
82 suggests that these congenital pancreatic defects occur in response to environmental stimuli.

83 Pancreas development is difficult to observe during embryonic development in
84 mammalian models, as it requires highly invasive procedures. Building upon an understanding of
85 highly conserved vertebrate developmental processes, the zebrafish embryo is a well-established
86 model for studying pancreas development (reviewed in (Kinkel and Prince, 2009; Tiso et al.,
87 2009)). Because zebrafish embryos are transparent and fertilized externally, this allows for direct
88 visualization of developing pancreas structures throughout the developmental timecourse.

89 Both the endocrine and exocrine pancreas can be easily visualized during organogenesis
90 using transgenic zebrafish models (Tiso et al., 2009). The pancreas is formed from two anlagen
91 that emerge from the endoderm and fuse together and extend dorsally during organogenesis. The
92 endocrine pancreas houses the islets of Langerhans, which largely consist of the insulin-
93 producing beta cells, but also include other cell types that secrete hormones that regulate nutrient
94 metabolism and comprise the glucose homeostasis feedback system. These include alpha cells
95 that produce glucagon, delta cells that produce somatostatin, epsilon cells that produce ghrelin,
96 and gamma cells (also called pancreatic polypeptide cells) that produce pancreatic polypeptide.

97 The islets are embedded in the exocrine pancreas tissue, which functions to produce digestive
98 enzymes that drain into ducts feeding into the duodenum. Transgenic zebrafish, such as those
99 engineered to express fluorescent proteins in beta cells (*Tg(ins:GFP)*) and in the exocrine
100 pancreas tissue (*Tg(ptfla:GFP)*) (diIorio et al., 2002; Lin et al., 2004), present a unique
101 opportunity to study the effects of toxicant exposures on this sensitive target tissue in a live
102 vertebrate embryo in real time, and determine the relationship between toxicant exposures and
103 pancreatic defects.

104 One anthropogenic contaminant that might contribute to pancreatic malformations is
105 perfluorooctanesulfonic acid (PFOS), which has been repeatedly associated with metabolic
106 dysfunction. PFOS is a surfactant previously found in non-stick application products, such as
107 Teflon and Scotchgard, until it was phased out of production in the United States in 2002. It is
108 highly persistent in the environment and in the body, with a half-life of approximately 5 years in
109 human serum (Olsen et al., 2007), though estimated to be roughly 12 days in the blood of
110 rainbow trout (Martin et al., 2003). Humans are almost ubiquitously exposed to PFOS, which has
111 been detected in >98% of human serum samples (Calafat et al., 2007) and also found in human
112 pancreas tissue (Maestri et al., 2006). Detection in both cord blood and amniotic fluid samples
113 demonstrates that PFOS can also cross the placental barrier, indicating an exposure risk to the
114 developing fetus (Inoue et al., 2004; Toft et al., 2016). Numerous studies have associated PFOS
115 exposures with markers for metabolic syndrome and diabetes, such as elevated insulin and
116 cholesterol, insulin resistance, and altered beta cell function (Lin et al., 2009; Lv et al., 2013;
117 Nelson et al., 2010; Wan et al., 2014). However, the pathological consequences of PFOS
118 exposure for the fetal pancreas, as well as the underlying mechanism of PFOS-induced metabolic
119 dysfunction, remain unknown.

120 Our study objective was to identify whether embryonic exposure to PFOS may alter the
121 structure and function of the developing pancreas. We hypothesized that embryonic PFOS
122 exposures would reduce β cell mass and disrupt the glucoregulatory axis. Here, we utilize the
123 zebrafish embryo model to visualize malformations of the developing pancreas, and develop
124 criteria for use in an AOP to interrogate the developmental origins of metabolic dysfunction.

125

126 **MATERIALS & METHODS**

127 **CHEMICALS**

128 Heptadecafluorooctanesulfonic acid (PFOS) was purchased from Sigma-Aldrich (St.
129 Louis, MO). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Pittsburgh, PA).
130 Stock solutions [160-640 mM] for embryo exposures were prepared by dissolving PFOS into
131 DMSO, and stored at room temperature in glass bottles inside of light-prohibitive containers
132 until use. All experimental procedures involving PFOS were performed using appropriate safety
133 precautions.

134

135 **ANIMALS AND HUSBANDRY**

136 Transgenic zebrafish of the *Tg(ins:GFP)* (diIorio et al., 2002) and *Tg(ptf1a:GFP)* strains
137 were each obtained as a heterozygous population from Dr. Philip diIorio at the University of
138 Massachusetts Medical School (Worcester, MA) and bred in house to homozygosity. The
139 *Tg(ins-GFP)* strain expresses green fluorescence in the insulin-producing beta cells, allowing for
140 visualization of pancreatic islets. The *Tg(ptf1a:GFP)* strain expresses green fluorescence in the
141 exocrine pancreas tissues, and also in the retina and parts of the brain (Godinho et al., 2005; Lin
142 et al., 2004).

143 Adult fish were housed in an Aquaneering zebrafish system maintained at 28.5°C in
144 accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals
145 of the National Institutes of Health and with approval from the University of Massachusetts
146 Amherst Institutional Animal Care and Use Committee (Animal Welfare Assurance Number
147 A3551-01). Fish were maintained on a 14 h light:10 h dark daily cycle, and provided the
148 recommended amount of GEMMA Micro 300 (Skretting; Westbrook, ME) once daily. Breeding
149 populations were housed in tanks containing roughly 15 males and 30 females.

150 Embryos were collected from breeding tanks 0-1 hour post fertilization (hpf), washed,
151 and housed with no more than 25 other embryos in glass 100 mm petri dishes containing 0.3X
152 Danieau's medium (17 mM NaCl, 2 mM KCl, 0.12mM MgSO₄, 1.8mM Ca(NO₃)₂, 1.5mM
153 HEPES, pH 7.6) throughout the experiments.

154

155 **EXPOSURES**

156 At 3 hours post fertilization (hpf), embryos staged at the mid-blastula transition were
157 exposed to PFOS solutions with a total of 0.01% DMSO v/v in a total of 20 ml of 0.3X
158 Danieau's medium. Final concentrations of PFOS were 0 (DMSO control), 16, 32, or 64 μM,
159 and were refreshed daily to mimic subchronic developmental exposures. These concentrations
160 were chosen based upon exposures used in other zebrafish studies (Chen et al., 2014; Wang et
161 al., 2011; Zheng et al., 2011), and to optimize islet effects while minimizing effects on gross
162 anatomy and embryo survival. All embryos were manually dechorionated using watchmaker's
163 forceps at 24 hpf and debris removed from dishes prior to refreshing exposures. Experiments
164 were replicated 3-4 times on groups of 8-12 embryos per concentration.

165

166 **MICROSCOPY**

167 *Tg(ins-GFP)* embryos and larvae were imaged at 48, 96, and 168 hpf to observe
168 morphogenesis of the primary islet, and later formation of the secondary islets. *Tg(ptf1a-GFP)*
169 larvae were imaged at 96 and 168 hpf to observe the extension of the exocrine pancreas,
170 indicative of total pancreas length. All imaging was performed using an inverted fluorescence
171 microscope (EVOS FL Auto, Life Technologies, Pittsburgh, PA) equipped with a GFP filter.
172 Embryos and larvae were washed thoroughly and briefly anaesthetized in 2% v/v MS-222
173 solution (prepared as 4 mg/ml tricaine powder in water, pH buffered, and stored at -20°C until
174 use). Embryos and larvae were mounted in drops of 3% methylcellulose for imaging, and
175 oriented for optimal pancreas visualization. Images were acquired using 10X and 20X objectives
176 for magnification of islets, and 4X magnification for exocrine pancreas visualization. Because
177 images were obtained on an inverted microscope, images presented in figures have been mirror-
178 flipped to reflect the actual orientation.

179

180 **RNA ISOLATION AND REVERSE TRANSCRIPTION**

181 RNA was collected from embryos at 48 hpf and 96 hpf for targeted examination of
182 pancreas-relevant gene expression. Embryos were collected into RNAlater (Fisher Scientific)
183 and stored at -80°F until RNA isolation. At 48 hpf, 8-10 embryos were pooled per sample for a
184 total of 6-9 samples per exposure group; at 96 hpf, 5-7 eleutheroembryos were pooled per sample
185 for a total of 4-5 samples per exposure group. Eleutheroembryos are those that have hatched, but
186 are not yet independently feeding and are still dependent on their yolk for nutrition.

187 Samples were processed with the GeneJET RNA Purification Kit (Fisher Scientific;
188 Waltham, MA) according to manufacturer instructions. RNA concentrations were determined
189 using a BioDrop μ LITE spectrophotometer (BioDrop; Cambridge, UK). For 48 hpf samples, 500
190 ng RNA underwent reverse transcription for cDNA conversion using the iScript cDNA Synthesis
191 Kit (Bio-Rad). For 96 hpf samples, 1 μ g of RNA was reverse transcribed into cDNA. Upon
192 completion, cDNA was stored at -20°C until use.

193

194 **QUANTITATIVE PCR**

195 Prior to qPCR, cDNA was diluted to a working stock of 0.25 ng/ μ l for use in reactions.
196 Quantitative PCR was performed using a Bio-Rad CFX Connect Real-Time PCR Detection
197 System in a 20 μ l reaction mixture containing 10 μ l 2x iQ SYBR Green Supermix (Bio-Rad), 5
198 pM of each primer, 5 μ l water, and 1 ng (4 μ l) of cDNA template. Primers used in this study
199 have been previously published (Timme-Laragy et al., 2015). Previously designed and optimized
200 primers for β -actin (*actb*), beta-2-macroglobulin (*b2m*), and preproinsulin a (*insa*) are provided
201 in Supplementary Table 1. Endocrine pancreas gene expression was investigated at 48 and 96
202 hpf using commercially available PrimePCR primers (Bio-Rad) for pancreatic and duodenal
203 homeobox 1 (*pdx1*), somatostatin 2 (*sst2*), glucagon a (*gcga*), and ghrelin (*ghrl*). Exocrine
204 pancreas gene expression was examined at 96 hpf using PrimePCR primers for pancreas specific
205 transcription factor 1a (*ptf1a*), trypsin (*try*), chymotrypsinogen B1 (*ctrb1*), and pancreatic
206 amylase 2a (*amy2a*). Data was visualized and analyzed using the Bio-Rad CFX Manager
207 software, and fold-changes were calculated using the $\Delta\Delta\text{C}_T$ method (Livak and Schmittgen,
208 2001). Treatment did not significantly affect the expression the housekeeping genes, *actb* or
209 *b2m*, and all fold changes were standardized relative to *actb* expression.

210

211 **STATISTICAL ANALYSIS**

212 All data is presented as the mean \pm SEM. Independent t-tests and ANOVAs were used to
213 test for statistical significance using IBM SPSS software. Fisher's Exact Test was used to test for
214 significant differences in the prevalence of secondary islets and islet morphological variants. A
215 confidence level of 95% ($\alpha=0.05$) was used.

216

217 **RESULTS**

218 **ISLET SIZE**

219 Diabetic phenotypes are often characterized by decreased beta cell mass [reviewed in
220 (Akirav et al., 2008; Karaca et al., 2009; Matveyenko and Butler, 2008)]. To assess whether
221 PFOS exposures could reduce beta cell mass during development, we measured area of the beta
222 cells labeled with GFP driven by the *insulin* promoter. Primary islet size was quantified for
223 embryos at 48 hpf and eleutheroembryos at 96 hpf, a time point previously shown to be sensitive
224 to toxicological perturbation of pancreatic organogenesis (Timme-Laragy et al., 2015). At 48
225 hpf, islet area decreased following a non-monotonic response (Fig. 1). A decrease of islet area
226 was observed for 16 and 32 μ M PFOS exposures compared to controls, though there was a
227 moderate attenuation of this effect at the highest concentration of 64 μ M ($p<0.01$, $p=0.03$, and
228 $p=0.04$, respectively). For islet size in 96 hpf eleutheroembryos, a similar non-monotonic, U-
229 shaped response was observed. As at the earlier developmental stage, the most severe decrease of
230 islet area was observed in the eleutheroembryos exposed to 32 μ M PFOS ($p<0.01$).

231

232 **ISLET MORPHOLOGY**

233 To observe whether PFOS exposures could produce anomalous islet morphology in
234 addition to decreased islet areas, embryos and larvae were examined for morphological variants
235 of the primary islet at 48, 96, and 168 hpf. Normally, islets are spherical, compact, and located
236 near the 4th somite after 24 hpf. We previously identified several examples of anomalous islet
237 morphology from toxicological perturbation with PCB-126, including islet fragmentation,
238 ectopic beta cells, and hypomorphic islets (Timme-Laragy et al., 2015). Here, we also observed
239 these morphologies as well as several newly identified variants due to PFOS exposures. The
240 prevalence of total islet malformations was elevated in embryos and larvae at all time points for
241 all PFOS exposure concentrations respective to controls (Fig. 2A). The distribution of
242 morphologies was also time sensitive (Fig. 2B). At 48 hpf, 16, 32, and 64 μ M PFOS significantly
243 increased the incidence of anomalous morphologies ($p=0.05$, $p<0.01$, and $p<0.01$, respectively),
244 primarily due to an increased number of stunted islets, which appear as a thin row of beta cells
245 rather than a spherical mass. At 96 hpf, the frequency of total islet variants more than doubled
246 for all PFOS exposures due to increased incidence of islets that appeared hollow/ring-shaped or
247 fragmented, though these changes were not statistically significant ($p>0.05$). At 168 hpf, PFOS
248 increased islet variant frequency for 16 ($p>0.05$), and especially 32 and 64 μ M exposures
249 ($p=0.01$ and $p=0.04$), and hollow islet morphology was the most commonly observed variant.

250

251 **SECONDARY ISLETS**

252 The mature pancreas has many secondary islets throughout the length of its entire tissue,
253 which begin to appear in zebrafish between 5-7 dpf. The number of secondary islets in the
254 pancreas and timing of their development can be sensitive to pharmacological stimuli (Wang et
255 al., 2015). To assess whether PFOS alters the timing of secondary islet formation, the number of

256 larvae with secondary islets was quantified for all PFOS exposures (Fig. 3). Approximately 40%
257 of control larvae developed at least one secondary islet at 168 hpf. Compared to controls, the
258 number of PFOS-exposed larvae with secondary islets decreased following the same U-shaped,
259 non-monotonic response as observed with islet area. Larvae exposed to 32 μ M were more than
260 59% less likely to have begun developing secondary islets than controls ($p=0.04$), though there
261 were no significant differences between controls and 16 or 64 μ M PFOS exposed larvae.

262 **FISH GROWTH**

263 Endocrine disruption is often coupled with perturbations in developmental growth and
264 metabolic programming. Therefore, fish length at 168 hpf was measured to determine whether
265 the concentrations of PFOS exposure used in this study altered the overall growth of the embryos
266 and larvae (Fig. S1). Total fish length was unchanged in larvae exposed to 16 μ M PFOS. Larvae
267 exposed to 32 μ M ($p=0.07$) and 64 μ M PFOS were 2% ($p<0.01$) and 1.5% ($p=0.07$) smaller,
268 respectively. We observed no mortality. Because several other studies examined embryotoxicity
269 of PFOS in zebrafish and observed increased incidence of delayed swim bladder inflation and
270 spinal lordosis, we assessed these outcomes at 96 and 168 hpf respectively (Supplemental Table
271 2). There was a slight decrease in the percent of eleutheroembryos with inflated swim bladders at
272 96 hpf and an increase in the number of eleutheroembryos with lordosis at 168 hpf, though none
273 of these differences were statistically significant.

274

275 **PANCREAS LENGTH**

276 The pancreas is predominantly composed of exocrine tissue, which lengthens in the
277 posterior direction between 48-96 hpf during zebrafish development. Though primary islets form
278 in the region proximal to the gut (pancreas head), greater concentrations of secondary islets
279 develop throughout the distal body and tail regions of the pancreas once exocrine extension has

280 completed (Elayat et al., 1995; Wang et al., 2013; Wittingen and Frey, 1974). Pancreas length
281 has been inversely associated with incidence of diabetes in adulthood (Agabi and Akhigbe,
282 2016), likely due to the shortening of the islet-dense regions. Here, we wanted to observe
283 whether these shortened pancreases could be observed during development and whether
284 toxicological perturbation may contribute to this phenotype. Pancreas extension was observed at
285 96 and 168 hpf, and the length from the center of the primary islet to the posterior tip of the
286 exocrine pancreas was measured in *ptfla* transgenic fish (Fig. 4A). Pancreas length was
287 decreased by 7-20% at 96 hpf and by 1-7% at 168 hpf, both following the characteristic U-
288 shaped non-monotonic dose-response curve observed in our other measures (Fig. 4B). Pancreas
289 length was significantly decreased in 96 hpf eleutheroembryos exposed to 32 and 64 μ M PFOS,
290 with the greatest decrease occurring with exposure to 32 μ M ($p=0.01$ and $p=0.04$, respectively).
291 At 168 hpf, only larvae exposed to 32 μ M PFOS showed significant reduction of pancreas length
292 compared to controls compared to controls ($p=0.04$). The relative pancreas length was calculated
293 for each fish (pancreas length/fish length) to identify any associations between pancreas and total
294 body growth (Fig. S2). There were no significant changes in relative pancreas length due to
295 PFOS exposures, though there was a subtle, linear, dose-dependent decrease.

296

297

298 **ENDOCRINE GENE EXPRESSION**

299 Because PFOS produced structural changes of the developing pancreas in our embryos
300 and larvae, gene expression of endocrine pancreatic hormones and transcription factors was
301 quantified to observe whether any functional changes were produced by PFOS exposures. Here,
302 we quantified gene expression of several major hormones and endocrine transcription factors.

303 Insulin (*Insa*) is secreted by beta cells and stimulates the uptake of glucose from the blood into
304 tissues. Glucagon a (*Gcga*), the hormone stimulating breakdown of glucose stores into free
305 glucose, is secreted from islet alpha cells and often has an inverse relationship with insulin.
306 Somatostatin 2 (*Sst2*) belongs to a family of genes with a myriad of endocrinology roles,
307 including inhibition of *insa* expression, and is secreted from delta cells. Ghrelin (*Ghrl*), also an
308 inhibitor of *insa* expression, is produced in hunger conditions by the islet epsilon cells and
309 functions to counteract the action of the anorexic hormone leptin (produced by fat cells) in the
310 brain. Pancreatic and duodenal homeobox 1 (*Pdx1*) is an endocrine pancreas-specific
311 transcription factor that governs the expression of glucoregulatory genes, including *insa*.
312 Together, these hormones and factors help govern endocrine function and glucose homeostasis
313 for the entire organism.

314 Exposure to PFOS disrupted expression of genes which govern the glucoregulatory
315 hormone axis in islet cells. At 48 hpf, islet sizes and *insa* expression were not concordant, since
316 gene expression was unchanged by treatment. However, at 96 hpf, eleutheroembryos exposed to
317 32 and 64 μ M PFOS had reduced *insa* expression compared to controls at 96 hpf ($p < 0.01$ and
318 $p = 0.05$, respectively), which was concordant with islet size data (Fig. 5A). Expression of *gcga*
319 was relatively stable at both 48 and 96 hpf (Fig. 5B), but exposure to 64 μ M PFOS nearly
320 doubled expression ($p = 0.01$) at 96 hpf. Expression of transcription factor *pdx1* also nearly
321 doubled following 64 μ M PFOS exposure in 96 hpf eleutheroembryos ($p < 0.01$) compared to
322 controls (Fig. 5C), and was also significantly decreased by 32 μ M PFOS exposure in 48 hpf
323 embryos ($p = 0.04$).

324 Expression of *sst2* was decreased by more than 20% in 48 hpf embryos exposed to 32
325 μ M PFOS ($p = 0.05$; Fig. 5D). All PFOS exposures significantly decreased *sst2* expression in 96

326 hpf eleutheroembryos compared to controls ($p < 0.01$ for all concentrations), and followed a non-
327 monotonic U-shaped response curve. *Ghrelin* expression was sensitive to PFOS exposures at
328 both 48 and 96 hpf (Fig. 5E). Exposures of 16, 32, or 64 μM PFOS significantly decreased *ghrl*
329 expression in embryos by nearly 50% ($p = 0.03$, $p < 0.01$ and $p < 0.01$, respectively). This same
330 response was observed at 96 hpf, with the 16 and 64 μM exposures halving *ghrl* expression
331 ($p < 0.01$) and the 32 μM exposure decreasing expression by over 70% ($p < 0.01$).

332

333 **EXOCRINE GENE EXPRESSION**

334 Both the endocrine and exocrine pancreas play important roles in glucose homeostasis,
335 either through the secretion of glucoregulatory hormones into the vasculature or of digestive
336 peptides. Since pancreas length was shortened, as quantified by measuring the length of the
337 exocrine pancreas, we wanted to assess whether these structural changes co-occurred with gene
338 expression alterations that may be crucial for exocrine pancreas development and function.
339 Likewise, this would allow us to examine whether the effects of PFOS are specific to only the
340 endocrine pancreas. Expression of these genes was only characterized at 96 hpf, due to the lack
341 of exocrine architecture in the embryonic pancreas at 48 hpf. First, expression of transcription
342 factor *ptfla* was assessed to determine whether the altered exocrine pancreas structure, as
343 visualized by using the *Tg(ptfla-GFP)* transgenic line, is correlated with *ptfla* gene expression
344 (Fig. 6A). While an increasing trend was observed, there was no significant change in *ptfla*
345 expression.

346 We also measured expression of several digestive enzymes synthesized in the exocrine
347 pancreas. The dose-dependent expression profiles of the proteases trypsin (*try*, Fig. 6B) and
348 chymotrypsinogen B1 (*ctrb1*, Fig. 6C) were similar. Expression of *try* decreased at the 16 μM
349 ($p = 0.06$) and 32 μM concentrations, though was only statistically significant for the 32 μM

350 concentration ($p < 0.01$). Expression of *ctrb1* was significantly decreased at both the 16 and 32
351 μM PFOS concentrations ($p = 0.02$ and $p = 0.01$, respectively). For both proteases, the effect was
352 attenuated for the 64 μM treated eleutheroembryos. We also examined the expression of the
353 carbohydrate digestive enzyme *amy2a*, the form of amylase produced by the exocrine pancreas
354 (Fig. 6D). Expression of *amy2a* was also decreased by both the 16 μM ($p = 0.06$) and 32 μM
355 PFOS exposures, though only significantly for the 32 μM concentration ($p < 0.01$). Also similar to
356 the other proteases, this effect was attenuated in the embryos exposed to 64 μM .

357

358 **DISCUSSION**

359 Incidence of diabetes and metabolic syndrome, especially among children, has been
360 rapidly increasing in the United States, presenting an emerging public health and economic crisis
361 (D'Adamo and Caprio, 2011; Dabelea et al., 2014; Li et al., 2009; Silverstein et al., 2005).
362 Though genetics and lifestyle are well known to increase risk for these disorders, the
363 contribution of the chemical environment is not well understood. To better understand the
364 contributions of environmental toxicant exposures to the developmental origins of diabetes, we
365 investigated the health consequences of PFOS on organogenesis of the pancreas, an organ central
366 to digestive function and glucoregulation. We also propose new developmental criteria to
367 contribute to an AOP framework for the developmental origins of metabolic dysfunction using
368 the zebrafish model. Pancreatic organogenesis is a highly conserved process across vertebrates;
369 zebrafish are an ideal model for these studies due to the rapid development of transparent
370 embryos and availability of transgenic models which enable *in vivo* observation of the
371 developing pancreas in real time. Thus, we are able to quantify the effect of contaminants

372 directly in the pancreas of living vertebrate embryos. In this study, we investigated whether
373 embryonic exposure to the ubiquitous contaminant PFOS may disrupt pancreas development.

374 We observed increased incidence of hypomorphic and defective islets in PFOS-exposed
375 embryos and larvae compared to controls (Figs. 1 and 2). Since islet size and architecture have
376 been associated with both Type 1 and Type 2 diabetes, this data suggests that developmental
377 PFOS could increase risk for diabetes later in life. These observed morphologies, coupled with a
378 matching dose-response for hormone gene expression, suggest that the acute effects of PFOS
379 exposures during early development are likely to result in insulin deficiency. In this study,
380 *Tg(ins:gfp)* zebrafish were used to visualize islet architecture, specifically beta cells. We
381 observed altered size and morphology, but we cannot attribute this decrease to fewer beta cells.
382 In future work we will quantify whether the perturbations observed in this study translate to
383 decreased numbers of beta cells and/or impact the architecture, or influence other islet cell types
384 such as alpha cells.

385 With respect to the endocrine pancreas, we observed a similar dose response for many of
386 our morphological and gene expression endpoints. The high degree of concordance between
387 these endpoints suggests that pancreas morphologies and hormones might be predictive of each
388 other during embryonic development. If so, these measures could be utilized in an AOP
389 framework for understanding embryonic contributions to diabetes. Further, exocrine pancreas
390 endpoints such as pancreas length and digestive peptide expression also followed a U-shaped
391 dose-response when exposed to the same PFOS concentrations. This also suggests that
392 developmentally susceptible windows of the endocrine and exocrine pancreas tissues may be
393 similar.

394 Expression of *insa* was initially lowered by PFOS exposures, but attenuated by the highest
395 concentration (Fig. 5). This attenuation was complemented by nearly doubled expression of *pdx1*
396 and *gcga* at 96 hpf. These data suggest that this increased *pdx1* expression might directly
397 increase the expression of *insa* and *gcga* since *pdx1* serves as a transcription factor for the two
398 hormones. It is possible that this increase of *pdx1* expression causes the attenuation of islet
399 effects at the highest PFOS concentration for all of the islet morphology and gene expression
400 data, and future study of causality is necessary. The mechanism by which *pdx1* is induced by
401 PFOS exposure warrants further research, though it has been shown to be sensitive to oxidative
402 stress (Harmon et al., 2005; Hoarau et al., 2014; Kaneto et al., 1999). PFOS has been repeatedly
403 demonstrated to induce oxidative stress across a variety of tissues and model organisms,
404 including the zebrafish embryo (Chen et al., 2012; Hu et al., 2005; Liu et al., 2007; Shi and
405 Zhou, 2010). More work is required to explore the mechanisms by which oxidative stress may
406 influence these signaling pathways.

407 PFOS exposures increased the incidence of variant islets throughout development.
408 Exposures produced the greatest percentage of islet variants at 48 hpf, and these percentages
409 decreased until 7 dpf (Fig. 2). The decreasing percentage of islet variants suggests that either
410 these morphologies are not completely persistent or that compensation may occur. In particular,
411 the zebrafish has a greater regenerative capacity compared to humans. In this study, we utilized a
412 repeated daily PFOS exposure in order to minimize regenerative time and more closely mimic a
413 constant exposure produced by the human *in utero* environment. The incidence of variants
414 observed in the same population decreased between 2-7 dpf by 50-80%. Juvenile and adult
415 zebrafish could be used to study the resilience and sensitivity of beta cells during specific
416 windows of the lifecourse.

417 We have identified specific morphological islet variants during development. Because
418 pancreatic malformations have been associated with increased risk for diabetes, understanding
419 the causes and consequences of these anomalies could help us to improve and expand an AOP
420 for developmental contributions to diabetes and other pancreatic diseases (Balakrishnan et al.,
421 2006; Concepcion et al., 2014; Gentile and Fiorente, 1999; Gilinsky et al., 1987; Lindstrom et
422 al., 1990; Mitchell et al., 2004; Shoji et al., 2013). The prevalence of these morphological
423 variants within the control group suggests that there is some innate variability in these
424 developmental processes regardless of exposures, as we have recently shown (Sant et al., 2016).
425 The background prevalence of these variants in our controls of 3-8% falls within the estimated
426 background rate for humans based upon clinical data (Prasad et al., 2001; Varshney and Johnson,
427 1999; Vaughn et al., 1998). The variants observed in this study appear to be morphologically
428 congruent to developmental anomalies observed in humans, suggesting that the zebrafish may be
429 an appropriate model organism for studying and understanding human congenital pancreatic
430 defects.

431 We have shown that PFOS exposures during organogenesis may alter the length of the
432 pancreas (Fig. 4), a measure associated with diabetic phenotypes in humans. To our knowledge,
433 this is the first study to causally link embryonic exposures with congenitally shortened pancreas.
434 Because the majority of islets are eventually concentrated in the distal body and tail regions of
435 the pancreas, it is possible that a shortened pancreas could reduce the number of total islets due
436 to loss of habitable area. Dorsal pancreatic agenesis, the partial or complete lack of a pancreatic
437 tail, is uncommon, but rarely diagnosed due to the mild phenotypic consequences. The zebrafish
438 provides an excellent model to test for the relationship between pancreas length and metabolic
439 dysfunction, as the pancreas can be easily imaged in the living organism. Because of the novelty

440 of this finding, more work is necessary to understand the types of compounds that could affect
441 pancreas length, and the mechanisms by which they may act.

442 In this study, pancreas length was observed using *ptfla* transgenic zebrafish, where green
443 fluorescence is present throughout their exocrine pancreas. To validate these findings, we also
444 analyzed *ptfla* gene expression. Unexpectedly, *ptfla* expression was not significantly changed
445 and did not follow the same U-shaped response observed for pancreas length. Instead, there is an
446 increasing trend for *ptfla* gene expression (Fig. 6). Though this data did not confirm the exocrine
447 pancreas length dose-response, *ptfla* is not a pancreas-restricted transcription factor, and is an
448 important transcription factor in the central nervous system (Aldinger and Elsen, 2008; Kani et
449 al.; Pashos et al., 2013; Sellick et al., 2004). The hindbrain expression of *ptfla* was visible in our
450 embryo model (Fig. 4A). Because gene expression was quantified using whole embryos instead
451 of pancreas tissue alone, the contribution of these other tissues may be confounding this data and
452 therefore, *ptfla* may not be a good candidate for an AOP framework.

453 Though the pancreas length decreased, we also characterized gene expression of several
454 digestive enzymes to better understand whether the observed exocrine pancreas structure was
455 associated with altered exocrine function. Expression of proteases *try* and *ctrb1* as well as of the
456 glycolytic enzyme *amy2a* was decreased by 16 and 32 μ M PFOS exposures; however, this effect
457 was attenuated by 64 μ M PFOS exposure (Fig. 6). Though this dose-response does follow along
458 with pancreas length, it was interesting that the high-dose PFOS exposure was unable to produce
459 the structural and expression changes observed at lower concentrations. Further work should
460 investigate whether PFOS alters the uptake, distribution, and utilization of nutrients during
461 organogenesis, since these factors have been implicated in the developmental origins of diseases
462 such as diabetes.

463 This work provides several developmental outcomes of PFOS exposure in the pancreas.
464 However, the contributions of these pancreatic variants to overall developmental progress and
465 growth remain unknown. Here, a modest decrease of total larval length was measured due to
466 PFOS exposure. Though a 2% decrease of fish length is a mild phenotypic change, it is not
467 insignificant. In the United States, there is only a modest 4-6% difference in fetal length between
468 the median infant length and fetuses small for gestational age, defined as the lowest 10th
469 percentile for fetal growth (Fenton and Kim, 2013). A longitudinal study should be performed to
470 observe whether these pancreas morphologies and physiological consequences persist beyond
471 early developmental stages, or whether juvenile or adult fish are able to “catch up” and correct
472 for previous deficiencies. It is important to identify whether these developmental consequences
473 will ultimately manifest as metabolic dysfunction throughout the lifecourse in order to better
474 define prenatal parameters for interrogation in a developmental origins of diabetes AOP.

475 There are many gaps in our understanding of an AOP for the development of diabetes
476 produced by early life exposures. Numerous studies have examined epidemiological associations
477 between developmental exposures and metabolic dysfunction, or the pathological consequences
478 of toxicant exposures on adult beta cells. However, pancreas teratogenesis has rarely been
479 studied, but may provide a link between the embryonic biochemical and molecular changes and
480 the pathological outcomes later in life. In this study, we have addressed several of these gaps by
481 elucidating changes in gene expression and signaling, as well as structural anomalies in the
482 embryonic pancreas (Fig. 7, shown in bold). Future studies will further investigate the
483 mechanistic basis of these structural changes, and how they manifest as metabolic dysfunction
484 throughout the lifecourse.

485

486 **CONCLUSION**

487 In conclusion, we have identified specific morphological and likely functional
488 consequences of PFOS-induced perturbation of pancreatic organogenesis in both endocrine and
489 exocrine tissues for the purpose of expanding and improving an AOP. This work establishes a
490 foundation for future toxicology studies of the developing pancreas. We seek to establish a
491 predictive AOP framework for understanding the embryonic contributions to diabetes risk
492 through studying the mechanisms by which these morphological consequences may increase risk
493 for diabetes later in the lifecourse. In the future, we will continue to pursue the coordinated
494 characterization of the pancreatic biochemical, molecular, and morphological consequences of
495 toxicological perturbations during these newly identified key windows of developmental
496 susceptibility.

497

498

499 **ACKNOWLEDGEMENTS**

500 We are grateful to the late Dr. Philip J. diIorio for helpful conversations and guidance, as
501 well as providing the fish used in this study. We thank the following students for exceptional fish
502 care: Aviraj Basnet, Sarah Brown, Shana Fleischman, Sadia Islam, Yankel Karasik, Derek Luthi,
503 Karen Melendez, Michelle Rousseau, Paul Sinno, Christopher Sparages, Olivia Venezia, Felicia
504 Wang, Kaylee Williams, and Jiali Xu. The authors declare they have no actual or potential
505 competing financial interests.

506

507 **FUNDING**

508 This work was supported in part by the National Institutes of Health (R01 ES025748 to ART-L),
509 and a University of Massachusetts Amherst Commonwealth Honors College Research grant (to
510 KAB.).

511

512

513 **REFERENCES**

- 514 Agabi, J.O., Akhigbe, A.O., 2016. Comparative sonographic evaluation of the anteroposterior
515 dimensions of the pancreas in diabetics and nondiabetics. *Niger J Clin Pract* 19, 175-181.
- 516 Akirav, E., Kushner, J.A., Herold, K.C., 2008. β -Cell Mass and Type 1 Diabetes: Going, Going,
517 Gone? *Diabetes* 57, 2883-2888.
- 518 Aldinger, K.A., Elsen, G.E., 2008. Ptf1a Is a Molecular Determinant for Both Glutamatergic and
519 GABAergic Neurons in the Hindbrain. *The Journal of neuroscience* 28, 338-339.
- 520 Balakrishnan, V., Narayanan, V.A., Siyad, I., Radhakrishnan, L., Nair, P., 2006. Agenesis of the
521 dorsal pancreas with chronic calcific pancreatitis. case report, review of the literature and genetic
522 basis. *JOP* 7, 651-659.
- 523 Bosco, D., Armanet, M., Morel, P., Niclauss, N., Sgroi, A., Muller, Y.D., Giovannoni, L.,
524 Parnaud, G., Berney, T., 2010. Unique Arrangement of α - and β -Cells in Human Islets of
525 Langerhans. *Diabetes* 59, 1202-1210.
- 526 Cabrera, O., Berman, D.M., Kenyon, N.S., Ricordi, C., Berggren, P.-O., Caicedo, A., 2006. The
527 unique cytoarchitecture of human pancreatic islets has implications for islet cell function.
528 *Proceedings of the National Academy of Sciences of the United States of America* 103, 2334-
529 2339.
- 530 Calafat, A.M., Wong, L.Y., Kuklennyik, Z., Reidy, J.A., Needham, L.L., 2007. Polyfluoroalkyl
531 chemicals in the U.S. population: data from the National Health and Nutrition Examination
532 Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. *Environ Health*
533 *Perspect* 115, 1596-1602.
- 534 Chen, J., Tanguay, R.L., Tal, T.L., Bai, C., Tilton, S.C., Jin, D., Yang, D., Huang, C., Dong, Q.,
535 2014. Early life perfluorooctanesulphonic acid (PFOS) exposure impairs zebrafish
536 organogenesis. *Aquat Toxicol* 150, 124-132.
- 537 Chen, T., Zhang, L., Yue, J.-q., Lv, Z.-q., Xia, W., Wan, Y.-j., Li, Y.-y., Xu, S.-q., 2012.
538 Prenatal PFOS exposure induces oxidative stress and apoptosis in the lung of rat off-spring.
539 *Reproductive Toxicology* 33, 538-545.
- 540 Concepcion, J.P., Reh, C.S., Daniels, M., Liu, X., Paz, V.P., Ye, H., Highland, H.M., Hanis,
541 C.L., Greeley, S.A.W., 2014. Neonatal Diabetes, Gallbladder Agenesis, Duodenal Atresia, and
542 Intestinal Malrotation Caused by a Novel Homozygous Mutation in RFX6. *Pediatric diabetes* 15,
543 67-72.
- 544 D'Adamo, E., Caprio, S., 2011. Type 2 Diabetes in Youth: Epidemiology and Pathophysiology.
545 *Diabetes Care* 34, S161-S165.
- 546 Dabelea, D., Mayer-Davis, E.J., Saydah, S., et al., 2014. Prevalence of type 1 and type 2 diabetes
547 among children and adolescents from 2001 to 2009. *JAMA* 311, 1778-1786.
- 548 diIorio, P.J., Moss, J.B., Sbrogna, J.L., Karlstrom, R.O., Moss, L.G., 2002. Sonic hedgehog Is
549 Required Early in Pancreatic Islet Development. *Developmental Biology* 244, 75-84.

550 Elayat, A.A., el-Naggar, M.M., Tahir, M., 1995. An immunocytochemical and morphometric
551 study of the rat pancreatic islets. *Journal of Anatomy* 186, 629-637.

552 Evans, B.R., Karchner, S.I., Franks, D.G., Hahn, M.E., 2005. Duplicate aryl hydrocarbon
553 receptor repressor genes (*ahrr1* and *ahrr2*) in the zebrafish *Danio rerio*: Structure, function,
554 evolution, and AHR-dependent regulation in vivo. *Archives of Biochemistry and Biophysics*
555 441, 151-167.

556 Fenton, T.R., Kim, J.H., 2013. A systematic review and meta-analysis to revise the Fenton
557 growth chart for preterm infants. *BMC Pediatrics* 13, 1-13.

558 Gentile, M., Fiorente, P., 1999. Esophageal, duodenal, rectoanal and biliary atresia, intestinal
559 malrotation, malformed/hypoplastic pancreas, and hypospadias: further evidence of a new
560 distinct syndrome. *Am J Med Genet* 87, 82-83.

561 Gilinsky, N.H., Lewis, J.W., Flueck, J.A., Fried, A.M., 1987. Annular pancreas associated with
562 diffuse chronic pancreatitis. *Am J Gastroenterol* 82, 681-684.

563 Godinho, L., Mumm, J.S., Williams, P.R., Schroeter, E.H., Koerber, A., Park, S.W., Leach, S.D.,
564 Wong, R.O.L., 2005. Targeting of amacrine cell neurites to appropriate synaptic laminae in the
565 developing zebrafish retina. *Development* 132, 5069-5079.

566 Harmon, J.S., Stein, R., Robertson, R.P., 2005. Oxidative Stress-mediated, Post-translational
567 Loss of MafA Protein as a Contributing Mechanism to Loss of Insulin Gene Expression in
568 Glucotoxic Beta Cells. *Journal of biological chemistry* 280, 11107-11113.

569 Hoarau, E., Chandra, V., Rustin, P., Scharfmann, R., Duvillie, B., 2014. Pro-oxidant/antioxidant
570 balance controls pancreatic [beta]-cell differentiation through the ERK1/2 pathway. *Cell Death*
571 *Dis* 5, e1487.

572 Hu, W., Jones, P.D., Celius, T., Giesy, J.P., 2005. Identification of genes responsive to PFOS
573 using gene expression profiling. *Environmental Toxicology and Pharmacology* 19, 57-70.

574 Inadera, H., 2013. Developmental origins of obesity and type 2 diabetes: molecular aspects and
575 role of chemicals. *Environ Health Prev Med* 18, 185-197.

576 Inoue, K., Okada, F., Ito, R., Kato, S., Sasaki, S., Nakajima, S., Uno, A., Saijo, Y., Sata, F.,
577 Yoshimura, Y., Kishi, R., Nakazawa, H., 2004. Perfluorooctane Sulfonate (PFOS) and Related
578 Perfluorinated Compounds in Human Maternal and Cord Blood Samples: Assessment of PFOS
579 Exposure in a Susceptible Population during Pregnancy. *Environ Health Perspect.* 112, 1204–
580 1207.

581 Kaneto, H., Kajimoto, Y., Miyagawa, J., Matsuoka, T., Fujitani, Y., Umayahara, Y., Hanafusa,
582 T., Matsuzawa, Y., Yamasaki, Y., Hori, M., 1999. Beneficial effects of antioxidants in diabetes:
583 possible protection of pancreatic beta-cells against glucose toxicity. *Diabetes* 48, 2398-2406.

584 Kani, S., Bae, Y.-K., Shimizu, T., Tanabe, K., Satou, C., Parsons, M.J., Scott, E., Higashijima,
585 S.-i., Hibi, M., Proneural gene-linked neurogenesis in zebrafish cerebellum. *Developmental*
586 *Biology* 343, 1-17.

587 Karaca, M., Magnan, C., Kargar, C., 2009. Functional pancreatic beta-cell mass: Involvement in
588 type 2 diabetes and therapeutic intervention. *Diabetes Metab* 35, 77-84.

589 Kilimnik, G., Zhao, B., Jo, J., Periwal, V., Witkowski, P., Misawa, R., Hara, M., 2011. Altered
590 Islet Composition and Disproportionate Loss of Large Islets in Patients with Type 2 Diabetes.
591 PLoS ONE 6, e27445.

592 Kim, A., Miller, K., Jo, J., Kilimnik, G., Wojcik, P., Hara, M., 2009. Islet architecture: A
593 comparative study. *Islets* 1, 129-136.

594 Kinkel, M.D., Prince, V.E., 2009. On the diabetic menu: Zebrafish as a model for pancreas
595 development and function. *BioEssays : news and reviews in molecular, cellular and*
596 *developmental biology* 31, 139-152.

597 Li, C., Ford, E.S., Zhao, G., Mokdad, A.H., 2009. Prevalence of Pre-Diabetes and Its Association
598 With Clustering of Cardiometabolic Risk Factors and Hyperinsulinemia Among U.S.
599 Adolescents: National Health and Nutrition Examination Survey 2005–2006. *Diabetes Care* 32,
600 342-347.

601 Lin, C.Y., Chen, P.C., Lin, Y.C., Lin, L.Y., 2009. Association among serum perfluoroalkyl
602 chemicals, glucose homeostasis, and metabolic syndrome in adolescents and adults. *Diabetes*
603 *Care* 32, 702-707.

604 Lin, J.W., Biankin, A.V., Horb, M.E., Ghosh, B., Prasad, N.B., Yee, N.S., Pack, M.A., Leach,
605 S.D., 2004. Differential requirement for *ptf1a* in endocrine and exocrine lineages of developing
606 zebrafish pancreas. *Developmental Biology* 274, 491-503.

607 Lindstrom, E., von Schenck, H., Ihse, I., 1990. Pancreatic exocrine and endocrine function in
608 patients with pancreas divisum and abdominal pain. *Int J Pancreatol* 6, 17-24.

609 Liu, C., Yu, K., Shi, X., Wang, J., Lam, P.K.S., Wu, R.S.S., Zhou, B., 2007. Induction of
610 oxidative stress and apoptosis by PFOS and PFOA in primary cultured hepatocytes of freshwater
611 tilapia (*Oreochromis niloticus*). *Aquatic Toxicology* 82, 135-143.

612 Livak, K.J., Schmittgen, T.D., 2001. Analysis of Relative Gene Expression Data Using Real-
613 Time Quantitative PCR and the 2- $\Delta\Delta$ CT Method. *Methods* 25, 402-408.

614 Lv, Z., Li, G., Li, Y., Ying, C., Chen, J., Chen, T., Wei, J., Lin, Y., Jiang, Y., Wang, Y., Shu, B.,
615 Xu, B., Xu, S., 2013. Glucose and lipid homeostasis in adult rat is impaired by early-life
616 exposure to perfluorooctane sulfonate. *Environ Toxicol* 28, 532-542.

617 Maestri, L., Negri, S., Ferrari, M., Ghittori, S., Fabris, F., Danesino, P., Imbriani, M., 2006.
618 Determination of perfluorooctanoic acid and perfluorooctanesulfonate in human tissues by liquid
619 chromatography/single quadrupole mass spectrometry. *Rapid Communications in Mass*
620 *Spectrometry* 20, 2728-2734.

621 Martin, J.W., Mabury, S.A., Solomon, K.R., Muir, D.C.G., 2003. Bioconcentration and tissue
622 distribution of perfluorinated acids in rainbow trout (*Oncorhynchus mykiss*). *Environmental*
623 *Toxicology and Chemistry* 22, 196-204.

624 Matveyenko, A.V., Butler, P.C., 2008. Relationship between β -cell mass and diabetes onset.
625 *Diabetes Obes Metab* 10, 23-31.

626 Mitchell, J., Punthakee, Z., Lo, B., Bernard, C., Chong, K., Newman, C., Cartier, L., Desilets, V.,
627 Cutz, E., Hansen, I.L., Riley, P., Polychronakos, C., 2004. Neonatal diabetes, with hypoplastic

628 pancreas, intestinal atresia and gall bladder hypoplasia: search for the aetiology of a new
629 autosomal recessive syndrome. *Diabetologia* 47, 2160-2167.

630 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2014. National
631 Diabetes Information Clearinghouse (NDIC).

632 Nelson, J.W., Hatch, E.E., Webster, T.F., 2010. Exposure to Polyfluoroalkyl Chemicals and
633 Cholesterol, Body Weight, and Insulin Resistance in the General U.S. Population. *Environmental*
634 *health perspectives* 118, 197-202.

635 Olsen, G.W., Burris, J.M., Ehresman, D.J., Froehlich, J.W., Seacat, A.M., Butenhoff, J.L., Zobel,
636 L.R., 2007. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate,
637 and perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect*
638 115, 1298-1305.

639 Pashos, E., Park, J.T., Leach, S., Fisher, S., 2013. Distinct enhancers of *ptf1a* mediate
640 specification and expansion of ventral pancreas in zebrafish. *Developmental Biology* 381, 471-
641 481.

642 Prasad, T.R., Gupta, S.D., Bhatnagar, V., 2001. Ectopic pancreas associated with a choledochal
643 cyst and extrahepatic biliary atresia. *Pediatric Surgery International* 17, 552-554.

644 Sant, K., Jacobs, H., Xu, J., Borofski, K., Moss, L., Moss, J., Timme-Laragy, A., 2016.
645 Assessment of Toxicological Perturbations and Variants of Pancreatic Islet Development in the
646 Zebrafish Model. *Toxics* 4, 20.

647 Sellick, G.S., Barker, K.T., Stolte-Dijkstra, I., Fleischmann, C., J Coleman, R., Garrett, C.,
648 Gloyn, A.L., Edghill, E.L., Hattersley, A.T., Wellauer, P.K., Goodwin, G., Houlston, R.S., 2004.
649 Mutations in *PTF1A* cause pancreatic and cerebellar agenesis. *Nat Genet* 36, 1301-1305.

650 Shi, X., Zhou, B., 2010. The Role of *Nrf2* and *MAPK* Pathways in PFOS-Induced Oxidative
651 Stress in Zebrafish Embryos. *Toxicological Sciences* 115, 391-400.

652 Shoji, F., Takeo, S., Shikada, Y., Katsura, M., 2013. Anterior mediastinal gastroenteric cyst
653 containing pancreatic tissue influenced the diabetes mellitus status. *Interactive Cardiovascular*
654 *and Thoracic Surgery* 16, 413-415.

655 Silverstein, J., Klingensmith, G., Copeland, K., Plotnick, L., Kaufman, F., Laffel, L., Deeb, L.,
656 Grey, M., Anderson, B., Holzmeister, L.A., Clark, N., 2005. Care of Children and Adolescents
657 With Type 1 Diabetes: A statement of the American Diabetes Association. *Diabetes Care* 28,
658 186-212.

659 Simmons, R.A., 2006. Developmental origins of diabetes: The role of oxidative stress. *Free*
660 *Radical Biology and Medicine* 40, 917-922.

661 Simmons, R.A., 2007. Developmental origins of diabetes: the role of epigenetic mechanisms.
662 *Curr Opin Endocrinol Diabetes Obes* 14, 13-16.

663 Timme-Laragy, A., Sant, K., Rousseau, M., diIorio, P., 2015. Deviant development of pancreatic
664 beta cells from embryonic exposure to PCB-126 in zebrafish. *Comp Biochem Physiol C Toxicol*
665 *Pharmacol.* 178, 25-32.

666 Tiso, N., Moro, E., Argenton, F., 2009. Zebrafish pancreas development. *Mol Cell Endocrinol*
667 312, 24-30.

668 Toft, G., Jönsson, B.A.G., Bonde, J.P., Nørgaard-Pedersen, B., Hougaard, D.M., Cohen, A.,
669 Lindh, C.H., Ivell, R., Anand-Ivell, R., Lindhard, M.S., 2016. Perfluorooctane Sulfonate
670 Concentrations in Amniotic Fluid, Biomarkers of Fetal Leydig Cell Function, and
671 Cryptorchidism and Hypospadias in Danish Boys (1980–1996). *Environmental health*
672 *perspectives* 124, 151-156.

673 Varshney, S., Johnson, C.D., 1999. Pancreas divisum. *Int J Pancreatol* 25, 135-141.

674 Vaughn, D.D., Jabra, A.A., Fishman, E.K., 1998. Pancreatic disease in children and young
675 adults: evaluation with CT. *Radiographics* 18, 1171-1187.

676 Wan, H.T., Zhao, Y.G., Leung, P.Y., Wong, C.K.C., 2014. Perinatal Exposure to
677 Perfluorooctane Sulfonate Affects Glucose Metabolism in Adult Offspring. *PLoS ONE* 9,
678 e87137.

679 Wang, G., Rajpurohit, S.K., Delaspre, F., Walker, S.L., White, D.T., Ceasrine, A., Kuruvilla, R.,
680 Li, R.J., Shim, J.S., Liu, J.O., Parsons, M.J., Mumm, J.S., 2015. First quantitative high-
681 throughput screen in zebrafish identifies novel pathways for increasing pancreatic beta-cell mass.
682 *Elife* 4.

683 Wang, M., Chen, J., Lin, K., Chen, Y., Hu, W., Tanguay, R.L., Huang, C., Dong, Q., 2011.
684 CHRONIC ZEBRAFISH PFOS EXPOSURE ALTERS SEX RATIO AND MATERNAL
685 RELATED EFFECTS IN F1 OFFSPRING. *Environmental Toxicology and Chemistry / Setac*
686 30, 2073-2080.

687 Wang, X., Misawa, R., Zielinski, M.C., Cowen, P., Jo, J., Periwal, V., Ricordi, C., Khan, A.,
688 Szust, J., Shen, J., Millis, J.M., Witkowski, P., Hara, M., 2013. Regional Differences in Islet
689 Distribution in the Human Pancreas - Preferential Beta-Cell Loss in the Head Region in Patients
690 with Type 2 Diabetes. *PLoS ONE* 8, e67454.

691 Wilfinger, A., Arkhipova, V., Meyer, D., 2013. Cell type and tissue specific function of islet
692 genes in zebrafish pancreas development. *Developmental Biology* 378, 25-37.

693 Wittingen, J., Frey, C.F., 1974. Islet concentration in the head, body, tail and uncinat process of
694 the pancreas. *Ann Surg* 179, 412-414.

695 Zheng, X.M., Liu, H.L., Shi, W., Wei, S., Giesy, J.P., Yu, H.X., 2011. Effects of perfluorinated
696 compounds on development of zebrafish embryos. *Environ Sci Pollut Res Int* 19, 2498-2505.

697

698

699

700 **FIGURE CAPTIONS**

701 Fig 1. PFOS decreases islet area at 48 and 96 hpf. Islet area was measured in *Tg(insulin-GFP)*
702 embryos using EVOS software. Islet area was decreased along a U-shaped curve. Asterisks (*)
703 indicate a difference between designated treatment group and the controls ($p < 0.05$); $n = 30-45$
704 embryos at 48 hpf; $n = 20-25$ eleutheroembryos at 96 hpf

705
706 Fig 2. PFOS exposure increases the frequency of anomalous pancreas morphologies during
707 development. (A) Islet morphology was examined in *Tg(insulin-GFP)* transgenic fish at 48, 96,
708 and 168 hpf after subchronic PFOS exposure beginning at 3 hpf. Islets were screened for
709 fragmentation, hollowness, and severely stunted growth (shown in B at 20x magnification).
710 Numbers presented are the percent of embryos/larvae with variant islets. Italicized numbers are
711 the number of embryos/larvae sampled, cumulative across several study replicates. Fewer than
712 5% of embryos and larvae were severely deformed at the time of sampling, and were excluded
713 from pancreas imaging. The distribution of islet morphologies are shown in pie charts under each
714 respective time point, indicating a difference in the types of variants observed throughout
715 development. No significant temporal differences were observed. The position of the islet within
716 the zebrafish is shown (B, left). Asterisks (*) indicate a difference between designated treatment
717 group and the controls ($p < 0.05$); $n = 30-45$ embryos at 48 hpf; $n = 20-25$ eleutheroembryos at 96
718 hpf; $n = 24-29$ larvae at 168 hpf

719
720 Fig 3. PFOS exposure delays formation of secondary islets. (A) Secondary islets are
721 characterized by one or more beta cells developing after the primary islet (arrow), typically after
722 120 hpf. (B) The number of secondary islets at 7 dpf was quantified in *Tg(insulin-GFP)* larvae.

723 Incidence of islet defects was 19/47 (40%) in controls, 9/36 (25%) in the 16 μ M group, 6/36
724 (17%) in the 32 μ M group, and 13/43 (30%) in the 64 μ M group. Bars represent the percent of
725 larvae with secondary islets. Asterisks (*) indicate a difference between designated treatment
726 group and the controls ($p < 0.05$); $n = 36-47$ larvae per group.

727
728 Fig 4. PFOS exposure decreases exocrine pancreas length at 96 and 168 hpf. (A) Pancreas length
729 was measured in *Tg(ptfla-GFP)* transgenic fish, shown at 168 hpf. Pancreas length was
730 measured by quantifying the distance from the center of the islet (arrow) to the posterior tail of
731 the pancreas. A control pancreas of normal length is shown at left, and a PFOS-exposed and
732 shortened pancreas is shown at right. (B) Pancreas length is significantly decreased in fish
733 exposed to 32 and 64 μ M PFOS at 96 hpf, and to 32 μ M PFOS at 168 hpf. Asterisks (*) indicate
734 a difference between designated treatment group and the controls ($p < 0.05$); $n = 22-28$ larvae

735
736 Fig 5. Embryonic PFOS exposure alters pancreas endocrine gene expression. RNA was isolated
737 from embryos collected at 48 and 96 hpf, following subchronic PFOS exposure since 3 hpf.
738 Expression of *insa* (A), *gcga* (B), *pdx1* (C), *sst2* (D), and *ghrl* (E) was analyzed using qPCR and
739 the $\Delta\Delta C_T$ method. Bars represent the average fold change (relative to beta actin; shown on y-
740 axis) and the control group, and stars represent a PFOS-associated statistically significant change
741 of expression from the control group. Age of the embryos and eleutheroembryos is shown on the
742 x-axis in hpf. Asterisks (*) indicate a difference between designated treatment group and the
743 controls ($p < 0.05$); $n = 7-9$ samples of 9 pooled embryos at 48 hpf; $n = 4-5$ samples of 5 pooled
744 eleutheroembryos at 96 hpf

745

746 Fig 6. Embryonic PFOS exposure alters pancreas exocrine gene expression. RNA was isolated
747 from 96 hpf following subchronic PFOS exposure since 3 hpf. Expression of *ptfla* (A), *try* (B),
748 *ctrb1* (C), and *amy2a* (D) was analyzed using qPCR and the $\Delta\Delta C_T$ method. Bars represent the
749 average fold change (relative to beta actin; shown on y-axis) and the control group, and stars
750 represent a PFOS-associated statistically significant change of expression from the control group.
751 Asterisks (*) indicate a difference between designated treatment group and the controls ($p < 0.05$);
752 $n = 4-5$ samples of 5 pooled eleutheroembryos at 96 hpf

753
754 Fig 7. This study helps to expand an AOP framework for the developmental origins of metabolic
755 dysfunction and diabetes. Findings of this study (highlighted in black boxes) provide new criteria
756 for use in an AOP framework for the association between developmental exposures and
757 metabolic dysfunction. This framework (flowing from left to right) has guided the identification
758 of several key biochemical, molecular, cellular, and organ changes that lead to these disorders;
759 however, the effects of exposures such as PFOS on pancreas structure had not been studied. In
760 the future, we seek to elucidate a mechanism by which these exposures may cause
761 dysmorphogenesis of the endocrine and exocrine pancreas, and further how these structural
762 anomalies are associated with the development of metabolic dysfunction later in the lifecycle.

763
764 Supplemental Figure 1. Embryonic PFOS exposures affect overall fish growth. Fish length at
765 168 hpf was not affected in the 16 or 64 μM exposure groups, though a significant decrease in
766 fish length was observed in those exposed to 32 μM PFOS ($p < 0.01$). Asterisks (*) indicate a
767 difference between designated treatment group and the controls ($p < 0.05$); $n = 24-30$ larvae

768

769

770 Supplemental Figure 2. Embryonic PFOS exposures produce only a modest change in the
771 relative lengths of the pancreas. There is a linear, dose-dependent decrease in the relative length
772 of the pancreas (pancreas length/total larval length), though this change is not statistically
773 significant. n=24-30 larvae

774

775 **SUPPLEMENTAL TABLES**

776

777 **Supplemental Table 1.** Quantitative PCR primer sequences.

Gene	Forward primer (5'-3') Reverse primer (5'-3')	T_m	Reference
<i>actb</i>	CAACAGAGAGAAGATGACACAGATCA GTCACACCATCACCAGAGTCCATCAC	65	Evans <i>et al.</i> , 2005
<i>b2m</i>	CTGAAGAACGGACAGGTTATGT ACGCTGCAGGTATATTCATCTC	58	
<i>insa</i>	GCCCAACAGGCTTCTTCTACAAC GCAGATTTAGGAGGAAGGAAACCC	63	Wilfinger <i>et al.</i> , 2013

778

779

780 **Supplemental Table 2.** Observed embryo deformities following PFOS exposures.

Exposure	% Inflated Swim Bladder (96 hpf)	% Spinal Deformities (168 hpf)
Control (DMSO)	83%	4%
PFOS (16 μ M)	77%	22%
PFOS (32 μ M)	75%	28%
PFOS (64 μ M)	78%	28%

781

782